Node-positive breast cancer: Which are the best chemotherapy regimens?

Breast cancer-associated mortality has been significantly reduced
since the 1990s, mainly because of early diagnosis and systemic
therapeutic interventions. All three therapy components-cytostatic
therapy, endocrine therapy and targeted antibody therapy-are at
present necessary tools for the curative treatment of primary
breast cancer. This article reviews the evidence base for the use
of various chemotherapy schedules in patients with primary,
node-positive breast cancer, including schedules in combination
with targeted HER2/neu therapy.